{"id":746096,"date":"2023-04-07T16:03:28","date_gmt":"2023-04-07T20:03:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/"},"modified":"2023-04-07T16:03:28","modified_gmt":"2023-04-07T20:03:28","slug":"chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/","title":{"rendered":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, April  07, 2023  (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023 (the \u201cInducement Grants\u201d) for sixteen new employees pursuant to the Company\u2019s 2022 Equity Inducement Plan.<\/p>\n<p>The Inducement Grants have an exercise price per share equal to $23.15, the closing price per share of Chinook\u2019s common stock on March 31, 2023. The stock options vest over four years, with 25% vesting on the one year anniversary of each employee\u2019s start date and 1\/36<sup>th<\/sup> of the shares vesting monthly thereafter, subject to each employee\u2019s continued employment on each such date. The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement. The restricted stock units vest annually over three years beginning on the anniversary of the grant date for such awards.<\/p>\n<p>The Company granted the stock options and restricted stock units as a material inducement to these employees for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).<\/p>\n<p>\n        <strong>About Chinook Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook\u2019s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook\u2019s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1\/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook\u2019s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W8badZ6y4Q0lLkUYKX6kBjfGmUINy7KABPi_R7n5MVxNyHrftHH3fuyRgTSyrGaHiqA6NH6aCtfBXdQ3D8Ehig==\" rel=\"nofollow noopener\" target=\"_blank\">www.chinooktx.com<\/a>.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDM4Mjg2ODMtNzM5MS00YjU0LThlZTgtZGE1ZjA1ODc2YTM1LTEwMjI3NjA=\/tiny\/Chinook-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact:\r\nNoopur Liffick\r\nSenior Vice President, Investor Relations &amp; Corporate Communications\r\ninvestors@chinooktx.com\r\nmedia@chinooktx.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, April 07, 2023 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023 (the \u201cInducement Grants\u201d) for sixteen new employees pursuant to the Company\u2019s 2022 Equity Inducement Plan. The Inducement Grants have an exercise price per share equal to $23.15, the closing price per share of Chinook\u2019s common stock on March 31, 2023. The stock options vest over four years, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746096","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, April 07, 2023 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023 (the \u201cInducement Grants\u201d) for sixteen new employees pursuant to the Company\u2019s 2022 Equity Inducement Plan. The Inducement Grants have an exercise price per share equal to $23.15, the closing price per share of Chinook\u2019s common stock on March 31, 2023. The stock options vest over four years, &hellip; Continue reading &quot;Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-07T20:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-04-07T20:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/\"},\"wordCount\":405,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/\",\"name\":\"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\",\"datePublished\":\"2023-04-07T20:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/","og_locale":"en_US","og_type":"article","og_title":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SEATTLE, April 07, 2023 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company\u2019s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023 (the \u201cInducement Grants\u201d) for sixteen new employees pursuant to the Company\u2019s 2022 Equity Inducement Plan. The Inducement Grants have an exercise price per share equal to $23.15, the closing price per share of Chinook\u2019s common stock on March 31, 2023. The stock options vest over four years, &hellip; Continue reading \"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-07T20:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-04-07T20:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/"},"wordCount":405,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/","name":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=","datePublished":"2023-04-07T20:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzczNCM1NTE0NzgwIzIwMTExODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746096"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746096\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}